<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917731</url>
  </required_header>
  <id_info>
    <org_study_id>2020P002873</org_study_id>
    <nct_id>NCT04917731</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Type A for Cold Intolerance Secondary to Digital Amputations and Replantations: A Pilot Study</brief_title>
  <official_title>Botulinum Toxin Type A for Cold Intolerance Secondary to Digital Amputations and Replantations: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be selected for cold intolerance after finger amputation or replantation. They&#xD;
      will be given Botox or placebo dose as treatment and assessed over 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: To assess the efficacy of botulinum toxin type A on treating cold intolerance&#xD;
      secondary to digital amputations, revascularizations, or replantations&#xD;
&#xD;
      Primary null hypothesis: Randomized subjects who receive botulinum toxin type A injections&#xD;
      for pain associated with cold intolerance will experience similar changes in pain as compared&#xD;
      to patients randomized to receive saline injections (control)&#xD;
&#xD;
      • As measured by the Cold Insensitivity and Severity Score (CISS) at one week, four weeks,&#xD;
      and twelve weeks&#xD;
&#xD;
      Aim 2: To assess the safety of botulinum toxin type A on treating cold intolerance secondary&#xD;
      to digital amputations and replantations&#xD;
&#xD;
      Hypothesis: Injection of botulinum toxin for cold intolerance secondary to digital&#xD;
      amputations and replantations is not associated with any adverse reactions&#xD;
&#xD;
      III. SUBJECT SELECTION All adult, English-speaking patients who present with cold intolerance&#xD;
      secondary to digital amputation or replantation will be approached and asked to participate&#xD;
      in the study.&#xD;
&#xD;
      Inclusion criteria Adults (≥18 years) diagnosed with cold intolerance secondary to digital&#xD;
      amputations, revascularizations, or replantations and a CISS score of 30 or higher (the&#xD;
      threshold for pathological cold intolerance)11 Ability to give informed consent&#xD;
&#xD;
      Exclusion criteria Adults ≥ 75 years old Inability or unwillingness to participate in CISS or&#xD;
      DASH survey Major medical comorbidity expected to worsen in the next 6 months Comorbid&#xD;
      chronic pain condition Severe and untreated mental health conditions or active substance&#xD;
      dependence Pregnant or breastfeeding Known hypersensitivity to botulinum toxin Patients with&#xD;
      a compromised respiratory function Pre-existing neuromuscular disorders Receiving therapy&#xD;
      with aminoglycosides, anticholinergic agents, and muscle relaxants Infection in the proposed&#xD;
      injection site&#xD;
&#xD;
      All patients who satisfy the inclusion/exclusion criteria will be eligible for enrollment.&#xD;
      Vulnerable populations will be excluded from this study.&#xD;
&#xD;
      IV. SUBJECT ENROLLMENT A total of twenty-eight patients will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">June 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cold Intolerance Severity Score</measure>
    <time_frame>3 months</time_frame>
    <description>index of cold intolerance, validated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>quick dash</measure>
    <time_frame>three months.</time_frame>
    <description>a validated measure of hand function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PHQ 9</measure>
    <time_frame>3 months</time_frame>
    <description>depression measure, validated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cold Intolerance</condition>
  <arm_group>
    <arm_group_label>Botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>Botox injected at digital artery</description>
    <arm_group_label>Botox</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (≥18 years) diagnosed with cold intolerance secondary to digital amputations,&#xD;
             revascularizations, or replantations and a CISS score of 30 or higher (the threshold&#xD;
             for pathological cold intolerance)11 Ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 75 years old Inability or unwillingness to participate in CISS or DASH survey&#xD;
             Major medical comorbidity expected to worsen in the next 6 months Comorbid chronic&#xD;
             pain condition Severe and untreated mental health conditions or active substance&#xD;
             dependence Pregnant or breastfeeding Known hypersensitivity to botulinum toxin&#xD;
             Patients with a compromised respiratory function Pre-existing neuromuscular disorders&#xD;
             Receiving therapy with aminoglycosides, anticholinergic agents, and muscle relaxants&#xD;
             Infection in the proposed injection site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jonathan M. Winograd, M.D.</investigator_full_name>
    <investigator_title>Visiting Surgeon, Associate Professor Harvard Medical School</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

